Semax vs Selank is a choice between two peptides from the same Moscow institute. They share a three-amino-acid tail and sit side by side in Russian pharmacies. After that, they part ways.
The short answer: Semax and Selank are Russian-developed heptapeptides given as nasal drops. Semax is mainly studied for memory, attention and stroke recovery, and raises the growth factor BDNF in animal brains. Selank is mainly studied for anxiety and acts on GABA and enkephalin pathways. The evidence points to Semax for focus and Selank for calm. No study has tested them together, and neither is FDA-approved.
Podcasts sell them as a matched pair: one to sharpen you, one to steady you. The trial record is thinner and stranger than that. Almost every human study comes from Russia, most carry the developers’ names, and ClinicalTrials.gov lists none at all. This page gives you three things the clinic blogs skip:
- Every human trial in one table, with the doses the studies used and an evidence grade.
- A goal-by-goal decision matrix for anxiety, focus, stress, sleep, depression, ADHD and stroke.
- The Nootroholic COA check: five products from four vendors, priced per mg and tested for identity by mass. One combination vial came with a certificate for a different peptide altogether.
| Semax | Selank | |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Built from | ACTH(4–7), a fragment of the stress hormone ACTH, plus Pro-Gly-Pro | Tuftsin, an immune-signalling fragment of antibody IgG, plus Pro-Gly-Pro |
| Main research use | Stroke, memory, attention | Anxiety, fatigue (neurasthenia), stress |
| Mechanism studied | Raises BDNF and its receptor TrkB (rats); amplifies stimulant-driven dopamine release (mice) | Shifts GABA-system gene activity (rats); slows enkephalin breakdown (human serum) |
| Status in Russia | Registered medicine: 0.1% drops (cognitive disorders) and 1% drops (acute ischaemic stroke). On the national essential-drugs list. | Registered medicine: 0.15% drops, classed as an anxiolytic |
| Status in the US, EU, UK | Not approved. FDA advisers voted 8–5 in July 2026 to allow pharmacy compounding; FDA staff opposed; no final rule. | Not approved. Not on the list pharmacies may compound from. |
| Route in human studies | Nasal only | Nasal only |
| Onset reported | Brain-network changes on fMRI 5–20 minutes after one dose (healthy adults). Label claims 20–24 hours of action. | Anxiety relief built over 14-day courses; lasted a week after stopping in one trial |
| Half-life in humans | Never measured. The FDA found no human pharmacokinetic study by any route. | No published human study found. Broken into fragments quickly in rat plasma. |
| Label side effects | Mild nasal irritation | Allergic reactions, bitter taste |
| Label exclusions | Anxiety disorders, acute psychosis, seizure history, pregnancy, breastfeeding; under 18 for the 1% form | Pregnancy, breastfeeding, under 18 |
| Price per mg | $1.33–$5.00 | $5.00 standalone; $2.70–$3.75 in blends |
What Is Semax?
Heptapeptide synthesized at the Russian Academy of Sciences’ Institute of Molecular Genetics.
The design started with a seven-residue fragment of ACTH, a hormone that activates cortisol production in the body.
The makers kept the first four residues and swapped the last three. The peptide is a stronger painkiller than ACTH (4-10) itself. A single nasal dose lasted 20 to 24 hours in animals and people. The adrenal glands aren’t pushed to make cortisol.
It is manufactured by Peptogen in two strengths:
- 0.1% drops (1 mg/mL): for memory and thinking disorders caused by poor blood flow to the brain, recovery after head injury or surgery, optic nerve atrophy and, on some label versions, “minimal brain dysfunction” in children.
- 1% drops (10 mg/mL) for the acute phase of moderate or severe ischaemic stroke, administered along with standard care.
Semax is on Russia’s official Vital and Essential Drugs List. 60 to 70% of a nasal dose is absorbed. Semax crosses the blood-brain barrier.
N-acetyl Semax
N-acetyl Semax amidate is not Russian medicine. N-acetyl Semax amidate, Ac-Semax-NH2, is a research-market variant with an acetyl group on the front end. The changes are described as extra potency. Only laboratory chemistry has been peer-reviewed.
Studies show that acetylation alters how the peptide binds to copper and zinc. No studies on human comparison with plain Semax. Its molecular mass also differs from plain Semax, which matters when reading a COA (see the buying section).
What Is Selank?
A synthetic heptapeptide derived from tuftsin, a four-amino-acid fragment of IgG. It has the same Pro-Gly-Pro tail as Semax. It is registered as a nasal anxiolytic in Russia.
Selank has anti-anxiety and antidepressant effects without sedative properties.
Additionally, it has also been studied for its cognitive-enhancing properties. It may also regulate the immune system, potentially benefitting immune system-related diseases.
In Russia, the following groups of conditions are included: anxiety states, panic attacks, neurasthenia (diminished ability to endure and become irritated), mood swings, sleep disorders, stress and adjustment disorders.
Selank’s pitch is an anxiolytic without sedation.
Sources 6
NA-Selank
Another research market innovation featuring the same end caps as N-acetyl semax. It’s not a registered medicine. There have been no human or animal studies published as of September 2026.
Semax vs Selank: Key Differences
The front half of the molecule is the main difference.
Semax’s front half is a hormone fragment linked to learning and brain repair.
Selank’s is an immune fragment linked to relaxation. Both have the same Pro-Gly-Pro tail. Semax research centres on BDNF and dopamine; Selank research centres on GABA and enkephalin.
How Semax works: BDNF and dopamine
One nasal dose of Semax raised hippocampal BDNF protein 1.4-fold and TrkB phosphorylation 1.6-fold in rats. The amount of BDNF messenger RNA increased trippled. The expression of one type of BDNF mRNA was also increased threefold.
BDNF helps neurons form and sustain connections. It’s for this reason Semax is called a memory peptide.
Experimental strokes on rats have shown that Semax primarily switches on immune and blood-vessel genes. This is the key to its protective effects.
The other half is dopamine. In mice, Semax intensifies amphetamine-induced dopamine release in the striatum. The FDA says this is a typical response to abuse drugs, like cocaine.
How Selank works: GABA and enkephalins
The connection of GABA to Selank appears to be indirect. Within an hour, one dose altered 45 of 84 nerve-signaling genes in rats, with the pattern following GABA. The researchers say that Selank indirectly affects the GABA system.
The opioid system plays a role as well. In mice, Selank’s calming effect was diminished by Naloxone.
The body’s own opioids are called enkephalins. In an anxiety trial conducted in 2008 Selank extended the half-life of enkephalins, which have rapid degradation.
What Marketing intersection leaves out
BDNF vs GABA split is mostly a sales pitch. The peptides blocked the enzyme that breaks down enkephalins in a 2001 study. Semax was the strongest of the two, having enzyme activity at 10 µM against Selank’s 20 µM.
The only human study to test both in one protocol found shared and distinct effects. A 2020 fMRI study of 52 healthy adults found that each peptide changed the connection between the right amygdala and the right temporal cortex.
Which is better for Anxiety, Focus or Depression?
For anxiety, Selank. Most successful trials were made with comparisons to benzodiazepines. The evidence suggests that Semax can help with focus and memory, but these are based on brain scans and the developers’ own reports – and not outcome trials. A controlled human trial for depression and/or ADHD is not listed in PubMed.
| Goal | Evidence points to | Best human evidence | Grade |
|---|---|---|---|
| Generalised anxiety | Selank | Three Russian trials (60–70 patients each) against or alongside benzodiazepines; no placebo arm | B |
| Stroke recovery | Semax | Controlled but unblinded Russian trials of 110 patients each; the only use with a registered label | B–C |
| Focus and memory (healthy) | Semax | fMRI changes in 24 healthy adults; developer reports of better attention in healthy men | C |
| Stress that blocks focus | Selank; Semax’s label excludes anxiety disorders | No trial of either peptide for this goal, and none of the two together | D |
| Sleep | Neither | Selank’s label lists sleep disorders, but we found no sleep trial | None |
| Depression | Neither | Rat studies for both peptides; no controlled human trial in PubMed | Animal |
| ADHD | Neither | A 2006 hypothesis paper and an old Russian label indication; no controlled trial | None |
Selank for anxiety
A 2008 randomized trial with 62 people with generalized anxiety disorder or neurasthenia found Selank (30 patients) was as effective as benzodiazepine medazepam (32). It also helps with fatigue. The effects lasted a week after the last dose, similar to those of phenazepam. None of the trials used a placebo, so expectation effects cannot be excluded. They all came from Moscow groups including Selank’s developers.
Semax for focus and ADHD
The case for Semax as a focus drug for healthy people rests on the developers’ 1997 review and a 2018 study of 24 volunteers. In that study, one dose of 1% Semax enlarged the brain’s default mode network on fMRI within 20 minutes. A changed brain scan isn’t better work. The ADHD claim is traced to a 2006 hypothesis paper arguing that Semax’s dopamine and BDNF effects might suit ADHD. We found no controlled ADHD trials.
Semax or Selank for depression
In a 2024 rat study of chronic stress, Semax reversed anhedonia (loss of pleasure) and restored hippocampal BDNF. Selank reduced depression-like behaviour in a 2008 rat study The FDA’s review found reports of Semax use in children with depression or tics, but no controlled adult trial exists for either peptide.
Can You Take Semax and Selank Together?
No study has given Semax and Selank together to people or animals. The pairing comes from forums and vendors, not trials. The closest data is from a 2020 fMRI study that gave 52 healthy adults Semax, Selank or a placebo on their own. Any claim about the combination is an exaggeration.
Three findings shape how researchers think about pairing:
- The peptides overlap. Both carry Pro-Gly-Pro, and both slow enkephalin breakdown. Semax is stronger at this. So the combination isn’t a clean “one for each pathway” design.
- The labels pull in opposite directions. Semax’s Russian label excludes people with anxiety disorders, the group Selank is registered for. The stress-plus-focus rationale for pairing them runs into Semax’s own exclusion.
- The only combination of Selank with a benzodiazepine. In a 2015 randomised trial of 70 patients, adding Selank to phenazepam brought a faster response and fewer side effects, such as memory problems and sedation.
Pre-mixed products add a practical problem. In our COA check, one Selank/Semax vial had no certificate of its own. The only Selank nasal spray we found was blended with DSIP. The more peptides shared in a vial, the more difficult it is to prove what’s inside.
Sources 7
What the studies show?
The human evidence for Semax and Selank is 11 studies of more than 770 people, all Russian and most co-authored by the developers. Stroke and anxiety have been studied in controlled trials. Healthy-volunteer data is limited to brain scans. No trial is registered on ClinicalTrials.gov, and no Western group has replicated any results.
| Study | n and population | Dose and route, as published | Design | Result |
|---|---|---|---|---|
| Gusev, 1997 Semax | 110 (30 Semax, 80 controls); acute ischaemic stroke | 12 mg/day (moderate) or 18 mg/day (severe), nasal, 5–10 days | Controlled, not randomised | Faster recovery of general and motor deficits |
| Alekseeva, 1999 Semax | 73; brain damage after oxygen loss | Not stated in abstract | Uncontrolled | Helped memory problems; some patients showed seizure-like EEG activity |
| Gusev, 2005 Semax | 187; chronic poor blood flow to the brain | Not stated in abstract | Comparative | Reported slower progression and fewer strokes and mini-strokes; well tolerated |
| Serdiuk, 2007 Semax | 27; motor neuron disease | 1% solution, nasal | Randomised, open | No effect on nerve decline or symptoms; better quality of life |
| Gusev, 2018 Semax | 110; stroke rehabilitation | 6,000 µg/day, two 10-day courses 20 days apart, nasal | Controlled, open | Higher blood BDNF; faster gains in daily-living score |
| Lebedeva, 2018 Semax | 24 healthy adults (14 Semax, 10 placebo) | 1% solution, single nasal dose | Placebo-controlled fMRI | Larger frontal default mode network 5–20 min after dosing |
| Panikratova, 2020 Both | 52 healthy adults | Semax, Selank or placebo, single dose | Placebo-controlled fMRI | Shared and distinct changes in amygdala connectivity |
| Zozulia, 2008 Selank | 62 (30 Selank, 32 medazepam); GAD and neurasthenia | Nasal; dose not stated in abstract | Randomised, active control | Anxiety relief equal to medazepam, plus less fatigue; longer enkephalin half-life |
| Uchakina, 2008 Selank | Anxiety and neurasthenia patients (n not in abstract) | 14-day course | Comparative | Shifts in immune signalling proteins |
| Medvedev, 2014 Selank | 60; anxiety and somatoform disorders | Not stated in abstract | Comparative vs phenazepam | Clear anxiety relief, mild cognitive benefit; effect lasted a week after stopping |
| Medvedev, 2015 Selank | 70 (40 Selank plus phenazepam, 30 phenazepam alone) | Not stated in abstract | Randomised | Faster response; fewer benzodiazepine side effects |
Sources 11
What it adds up to
Three weaknesses run through the record. First, none of the clinical-outcome trials was placebo-controlled and blinded. Second, the same research network, often including Semax and Selank’s co-developer Nikolay Myasoedov, wrote most of the papers. Third, most appear only in Russian-language journals with short English abstracts. The FDA reached a blunt verdict on Semax in 2026: the studies were small, some relevant outcomes weren’t reported, and the evidence did not show effectiveness for its nominated uses.
That isn’t proof that the peptides don’t work. It means the evidence has never been tested the way Western regulators demand.
Nasal Spray vs Injection: How Semax and Selank Reach the Brain
Every human study of Semax and Selank used nasal drops. The FDA found no published human study of injected Semax. Russian labelling reports that 60 to 70% of a nasal Semax dose is absorbed and that Semax crosses the blood-brain barrier. In rats, the nose delivered Selank to the brain better than injection into the abdomen or a vein, or delivery by stomach tube.
Route can change what a peptide does, not just how much arrives. In a 2016 mouse study, injected Selank increased GABA-receptor binding in the frontal cortex by 38%. The same peptide given through the nose left GABA receptors unchanged and raised NMDA-receptor binding in the hippocampus by 23% instead.
Both peptides are broken down fast in blood. Selank splits into smaller fragments, and one of them, Gly-Pro, reproduced many of Selank’s effects on immune genes in mice. Research vendors mostly ship freeze-dried powder in vials, a format no published human study has used. The FDA has flagged a specific worry about injected and sprayed peptides of uncertain purity: impurities and clumped peptide can provoke immune reactions.
Sources 6
Side Effects and Safety: What the Labels and the FDA Found
The side effects reported for Semax and Selank are mild: nasal irritation for Semax, and allergic reactions and a bitter taste for Selank. The larger issue is what hasn’t been studied. There are no human pharmacokinetic data for Semax, no long-term safety studies for either peptide, and no independent test of abuse potential.
Safety signals worth knowing
- Seizure-like EEG activity. In the 1999 study of 73 patients with brain damage after oxygen loss, some showed paroxysmal (seizure-like) EEG activity after Semax. The authors advised monitoring brain activity during the first dose. Semax’s label excludes people with a history of seizures.
- Bleeding. Semax acted as an anticoagulant and antithrombotic in rats. The FDA noted this could raise bleeding risk in vulnerable people or alongside blood-thinning drugs.
- Dopamine and abuse potential. Semax boosted amphetamine-driven dopamine release in mice. No one has run the standard abuse-liability studies.
- One US adverse-event report. The FDA’s FAERS database holds one report linked to Semax. A consumer had eye pain and burning after using 0.1% drops bought online in 2024, was hospitalised, and still had symptoms a year later.
- Selank and GABA drugs. A 2021 review in the Journal of Clinical Pharmacology grouped Selank with phenibut as “poorly studied Russian drugs with GABAergic mechanisms”. The authors noted that both are sold to US consumers as dietary supplements and called for abuse-potential testing before public access.
Who the labels and trials excluded
Russian labelling excludes pregnancy and breastfeeding for both peptides and under-18s for Selank and 1% Semax. Semax’s label also excludes acute psychosis, anxiety disorders and a history of seizures. The Semax label states that no studies have been done in pregnancy. Every trial in the table above ran for weeks, not years.
Legal Status in the US, UK, EU and Russia
Semax and Selank are registered medicines only in Russia. Neither is approved by the FDA, the EMA or the UK’s MHRA. In the US, Semax moved closer to legal pharmacy compounding in July 2026, but no final rule exists. Selank isn’t on the list that compounding pharmacies may use.
- Semax, US: The FDA placed Semax in Category 2, its list of substances with significant safety concerns for compounding. On 23–24 July 2026, the Pharmacy Compounding Advisory Committee voted 8–5, with one abstention, to recommend adding Semax to the 503A bulks list. FDA scientists had recommended against it, citing safety, effectiveness and characterisation gaps. The vote isn’t binding, and rulemaking may take until 2027 or longer.
- Selank, US: Selank acetate came off Category 2 in September 2024 after its nominator withdrew. It still isn’t on the bulks list, so pharmacies can’t compound it. It wasn’t on the July 2026 agenda.
- UK and EU: No marketing authorisation for either peptide.
- Russia: Both are registered medicines made by Peptogen. Semax is on the national essential-drugs list.
Buying Semax or Selank: Nootroholic COA Check
Only two of the five products we checked came with a certificate that proves identity by mass. An HPLC test shows that the powder is mostly one substance, not which one. Proving what’s in the vial takes mass spectrometry, which weighs the molecule, or a match against a reference standard. The masses below are the numbers to look for:
| Compound | Formula | Mass (Da) |
|---|---|---|
| Semax | C37H51N9O10S | 813.35 |
| N-acetyl Semax (free acid) | C39H53N9O11S | 855.36 |
| N-acetyl Semax amidate | C39H54N10O10S | 854.37 |
| Selank | C33H57N11O9 | 751.43 |
| NA-Selank (N-acetyl Selank amidate) | C35H60N12O9 | 792.46 |
We reviewed the public certificates for every Semax and Selank product sold by four US vendors on 25 September 2026:
| Product | Price | $/mg | Lab, lot, purity | Identity proof |
|---|---|---|---|---|
| Ascension Peptides Semax & Selank 10 mg vials | $50 each | $5.00 | Semax: MZ Biolabs, lot 30-01260229 (Feb 2026): 99.75%, 10.12 mg measured. Newer lot 30-05260628 from Kovera Labs (Jun 2026): 99.886%, 11.23 mg; endotoxin, sterility and heavy metals passed. Selank: MZ Biolabs, lot 29-01260229 (Feb 2026): 99.32%, 12.29 mg measured. A newer Kovera lot is listed without a direct link. | Mass spec. Semax: 813.41 Da measured vs 813.35 expected. The newer Kovera certificate names LC-MS but shows no mass. Selank: 751.47 Da measured vs 751.43 expected. |
| Elite Edge Biotech Semax 30 mg vial | $40 (list $79.99) | $1.33 | Baler Lab, report #8000018 (May 2026): 99.126%, 31 mg measured. Batch: “Unknown”. | Claimed only. LC-MS/MS named; no mass, spectrum or chromatogram shown. |
| Elite Edge Biotech Selank/Semax 10 + 10 mg vial | $75 (list $120) | $3.75 | The COA link opens a certificate for Oxytocin 5 mg. No Selank or Semax certificate found. | None. |
| NextGen Peptides DSIP/Selank spray, 50 mg in 15 mL | $135 | $2.70 (blend) | ILS Laboratories, lot DSIPSELA (18 Sep 2026): 99.14%, 51.67 mg total peptide. Sterility, endotoxin (0.149 EU/mL), heavy metals and fentanyl screen passed. | Partly. Reference-standard match reported for DSIP only. Selank’s share of the 51.67 mg isn’t reported. |
Ascension is the only vendor whose Semax and Selank certificates weigh the molecule, and both measured more peptide than the label claims. Elite Edge’s Semax is the cheapest per mg by a wide margin, but a certificate with an unknown batch can’t be matched to any vial. NextGen’s spray has the fullest safety panel of anything we checked. Its identity row names only DSIP, though, so the certificate can’t tell you how much Selank you’re getting.
- Mass spec: 813.41 Da (expected 813.35)
- Newer lot: 99.886%, 11.23 mg measured
- Endotoxin, sterility, heavy metals passed
- Mass spec: 751.47 Da (expected 751.43)
- 99.32% HPLC, 12.29 mg measured
- No endotoxin data on the linked lot
- Baler Lab: 99.126%, 31 mg measured
- Batch listed as “Unknown”
- No mass or spectrum shown
- ILS Labs: 99.14%, Sept 2026 lot
- Sterility, endotoxin, metals, fentanyl passed
- Identity confirmed for DSIP only
Sources 6
The N-acetyl naming trap
Limitless Biotech sells “N-Acetyl Semax” and “N-Acetyl Semax Amidate” as two separate products. Both pages list the same sequence (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2), the same formula, the same 854.97 g/mol weight and the same CAS number. Either the first product is really the amidate, or its specification is wrong. Prices sit behind a “research access” login. A mass-spec certificate settles it: 854.37 Da means amidate, 855.36 means the free acid, and 813.35 means plain Semax sold under a premium name.
Our best peptide vendors list explains how we vet sellers, and our guide on how to read a peptide COA walks through each line of a certificate.
Adamax and Other Analogues
Adamax is a research-market analogue sold as a modified Semax, and it has no peer-reviewed literature. A PubMed search in September 2026 returned no study of it. N-acetyl Semax and NA-Selank are in the same position: popular on vendor sites and absent from the literature. Our Adamax peptide guide covers what vendors claim and what can be checked.
For other brain-focused peptides, see our Dihexa guide, our page on Pinealon and our list of 72 peptides.
Semax vs Selank FAQ
Is Semax or Selank better for anxiety?
Selank has the stronger anxiety evidence. In a 2008 Russian trial of 62 patients, it relieved generalised anxiety as well as the benzodiazepine medazepam and also reduced fatigue. Semax’s Russian label excludes people with anxiety disorders. Neither peptide has a placebo-controlled anxiety trial, and neither is approved outside Russia.
Can you take Semax and Selank together?
No study has tested Semax and Selank together, in people or animals. The pairing comes from forums and vendors. The two overlap more than marketing suggests: both carry a Pro-Gly-Pro tail and both slow enkephalin breakdown. Semax’s label also excludes anxiety disorders, the condition Selank is registered for.
Are Semax and Selank FDA approved?
No. Semax and Selank are registered medicines only in Russia. In July 2026, an FDA advisory committee voted 8–5 to let pharmacies compound Semax, against FDA staff advice, but no final rule exists. Selank isn’t eligible for compounding. Outside Russia, both are sold only as research chemicals.
What is the difference between Semax and N-acetyl Semax?
Semax is the registered Russian peptide, Met-Glu-His-Phe-Pro-Gly-Pro, with a mass of 813.35 Da. N-acetyl Semax is a research-market variant with an acetyl group added and usually an amide cap too, giving 854.37 Da. No human study has compared them. A mass-spec COA shows which one a vial holds.
How long do Semax and Selank last?
Semax’s developers report that one nasal dose acts for 20 to 24 hours, and brain scans showed changes within 5 to 20 minutes. Selank’s anxiety effect built over 14-day courses and lasted a week after stopping in a 2014 trial. Nobody has measured either peptide’s half-life in humans.
Does Semax help with ADHD?
There’s no controlled evidence that Semax helps ADHD. The idea comes from a 2006 hypothesis paper arguing that Semax’s effects on dopamine and BDNF might suit the condition, and from an old Russian label indication for minimal brain dysfunction in children. No ADHD trial appears in PubMed or ClinicalTrials.gov.
Sources
Show all 36 sources
- Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID 11517472 Human
- Alekseeva GV, Bottaev NA, Goroshkova VV. Use of semax at a follow-up of patients with posthypoxic encephalopathy. Anesteziol Reanimatol. 1999;(1):40-3. PMID 10199046 Human
- Gusev EI, Skvortsova VI, Chukanova EI. Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency. Zh Nevrol Psikhiatr Im S S Korsakova. 2005;105(2):35-40. PMID 15792140 Human
- Serdiuk AV, Levitskiĭ GN, Miasoedov NF, Skvortsova VI, et al. The study of chronic partial denervation and quality of life in patients with motor neuron disease treated with semax. Zh Nevrol Psikhiatr Im S S Korsakova. 2007. PMID 18379501 Human
- Gusev EI, Martynov MYu, Kostenko EV, et al. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61-68. doi:10.17116/jnevro20181183261-68 Human
- Lebedeva IS, Panikratova YR, Sokolov OYu, et al. Effects of Semax on the default mode network of the brain. Bull Exp Biol Med. 2018. doi:10.1007/s10517-018-4234-3 Human
- Panikratova YR, Lebedeva IS, Sokolov OYu, et al. Functional connectomic approach to studying Selank and Semax effects. Dokl Biol Sci. 2020;490(1):9-11. doi:10.1134/S001249662001007X Human
- Zozulia AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID 18454096 Human
- Uchakina ON, Uchakin PN, Miasoedov NF, et al. Immunomodulatory effects of selank in patients with anxiety-asthenic disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-5. PMID 18577961 Human
- Medvedev VE, Tereshchenko ON, Israelian AIu, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22. PMID 25176261 Human
- Medvedev VE, Tereshchenko ON, Kost NV, et al. Optimization of the treatment of anxiety disorders with selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):33-40. doi:10.17116/jnevro20151156133-40 Human
- Ashmarin IP, Nezavibat’ko VN, Miasoedov NF, et al. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova. 1997;47(2):420-30. PMID 9173745 Review
- Comparative study of analgesic potency of ACTH4-10 fragment and its analog semax. Bull Exp Biol Med. 2007. doi:10.1007/s10517-007-0002-5 Animal
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54-60. doi:10.1016/j.brainres.2006.07.108 Animal
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. doi:10.1186/1471-2164-15-228 Animal
- Inozemtseva LS, Yatsenko KA, Glazova NYu, et al. Antidepressant-like and antistress effects of the ACTH(4-10) synthetic analogs Semax and Melanotan II on male rats in a model of chronic unpredictable stress. Eur J Pharmacol. 2024;984:177068. doi:10.1016/j.ejphar.2024.177068 Animal
- Kost NV, Sokolov OIu, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001;27(3):180-3. doi:10.1023/a:1011373002885 Lab
- Volkova A, Shadrina M, Kolomin T, et al. Selank administration affects the expression of some genes involved in GABAergic neurotransmission. Front Pharmacol. 2016;7:31. doi:10.3389/fphar.2016.00031 Animal
- Kozlovskiĭ II, Andreeva LA, Kozlovskaia MM, et al. The role of opioid system in peculiarities of anti-anxiety effect of peptide anxiolytic selank. Eksp Klin Farmakol. 2012;75(2):10-3. PMID 22550852 Animal
- Sarkisova KIu, Kozlovskiĭ II, Kozlovskaia MM. Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice. Zh Vyssh Nerv Deiat Im I P Pavlova. 2008;58(2):226-37. PMID 18661785 Animal
- Ashmarin IP, Baglikova KE, Edeeva SE, et al. A comparative analysis of distribution of glyprolines administered by various routes. Bioorg Khim. 2008;34(4):464-70. doi:10.1134/s1068162008040043 Animal
- Vasil’eva EV, Kondrakhin EA, Salimov RM, Kovalev GI. Comparison of pharmacological effects of heptapeptide selank after intranasal and intraperitoneal administration to BALB/c and C57BL/6 mice. Eksp Klin Farmakol. 2016;79(9):3-11. PMID 29787664 Animal
- Kolomin T, Morozova M, Volkova A, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014;58(1):50-5. doi:10.1016/j.molimm.2013.11.002 Animal
- Zolotarev IuA, Dadaian AK, Dolotov OV, et al. Evenly tritium-labeled peptides and their in vivo and in vitro biodegradation. Bioorg Khim. 2006;32(2):183-91. PMID 16637290 Animal
- Magrì A, Tabbì G, Giuffrida A, et al. Influence of the N-terminus acetylation of Semax, a synthetic analog of ACTH(4-10), on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem. 2016. doi:10.1016/j.jinorgbio.2016.08.013 Lab
- Tsai SJ. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. 2006 (print 2007;68(5):1144-6). doi:10.1016/j.mehy.2006.07.017 Hypothesis
- Doyno CR, White CM. Sedative-hypnotic agents that impact gamma-aminobutyric acid receptors: focus on flunitrazepam, gamma-hydroxybutyric acid, phenibut, and selank. J Clin Pharmacol. 2021;61 Suppl 2:S114-S128. doi:10.1002/jcph.1922 Review
- US Food and Drug Administration. FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026 (semax section, including FAERS search and safety review). fda.gov/media/193348
- McDermott Will & Schulte. Bulk-list bound? PCAC backs majority of peptides in two-day public meeting. July 2026. mcdermottlaw.com
- US Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. Accessed 25 September 2026. fda.gov
- Lexology. FDA removes certain peptide bulk drug substances from Category 2 of interim 503A bulks list, 2024. lexology.com
- Vidal (Russia). Semax 1% nasal drops, registration ЛП-№(010596)-(РГ-RU), 18 June 2025; Selank 0.15% nasal drops, registration ЛП-№(010951)-(РГ-RU), 15 July 2025. Semax · Selank
- RLS (Russia). Semax 0.1% nasal drops, prescribing information. rlsnet.ru
- Wikipedia. Semax; Selank. Accessed 25 September 2026. Semax · Selank
- ClinicalTrials.gov. Search for interventions “Semax” or “Selank”, 25 September 2026: no registered trials of either peptide.
- Vendor certificates reviewed 25 September 2026: Ascension Peptides (MZ Biolabs Semax lot 30-01260229 and Selank lot 29-01260229; Kovera Labs Semax report KVR-2026-E848E0, lot 30-05260628); Elite Edge Biotech (Baler Lab report #8000018, Semax 30 mg, batch “Unknown”; Selank/Semax product page linking COA_Oxytocin_5mg_2026-07-22); NextGen Peptides (ILS Laboratories COA-2026-BCO6YF, lot DSIPSELA, 18 September 2026); Limitless Biotech N-Acetyl Semax and N-Acetyl Semax Amidate product specifications.